- Home
- LDWY vs SBFM Comparison
LDWY vs SBFM Comparison
Compare LDWY & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- SBFM
- Stock Information
- Founded
- LDWY 1990
- SBFM 2006
- Country
- LDWY United States
- SBFM United States
- Employees
- LDWY N/A
- SBFM N/A
- Industry
- LDWY Advertising
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- SBFM Health Care
- Exchange
- LDWY Nasdaq
- SBFM Nasdaq
- Market Cap
- LDWY 6.7M
- SBFM 3.7M
- IPO Year
- LDWY 1991
- SBFM N/A
- Fundamental
- Price
- LDWY $3.42
- SBFM $3.14
- Analyst Decision
- LDWY
- SBFM
- Analyst Count
- LDWY 0
- SBFM 0
- Target Price
- LDWY N/A
- SBFM N/A
- AVG Volume (30 Days)
- LDWY 9.9K
- SBFM 90.8K
- Earning Date
- LDWY 11-11-2024
- SBFM 11-11-2024
- Dividend Yield
- LDWY N/A
- SBFM N/A
- EPS Growth
- LDWY N/A
- SBFM N/A
- EPS
- LDWY N/A
- SBFM N/A
- Revenue
- LDWY $24,813,000.00
- SBFM $30,481,982.00
- Revenue This Year
- LDWY N/A
- SBFM $86.70
- Revenue Next Year
- LDWY N/A
- SBFM $126.76
- P/E Ratio
- LDWY N/A
- SBFM N/A
- Revenue Growth
- LDWY N/A
- SBFM 109.82
- 52 Week Low
- LDWY $3.02
- SBFM $2.42
- 52 Week High
- LDWY $6.88
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- LDWY 46.04
- SBFM 52.62
- Support Level
- LDWY $3.34
- SBFM $2.85
- Resistance Level
- LDWY $3.66
- SBFM $3.05
- Average True Range (ATR)
- LDWY 0.20
- SBFM 0.14
- MACD
- LDWY 0.04
- SBFM 0.03
- Stochastic Oscillator
- LDWY 62.50
- SBFM 85.29
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.